At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
Sildenafil +1 moredrug
Likely dose
Sildenafil 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Crossover Study In Healthy Older Male Subjects To Evaluate The Pharmacokinetics And Safety Of An Orally Disintegrating Tablet Formulation Of Sildenafil Administered Without Water Under Fed Compared To Fasted Conditions
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Dec 6, 2010·Updated Feb 1, 2021
In Brief
A Phase 1 clinical trial evaluating Sildenafil for Erectile Dysfunction. Completed, enrolled 12 participants across 1 site.
Detailed Summary
This study will evaluate if an orally disintegrating tablet of sildenafil will have similar pharmacokinetic properties when given with food and without food.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsErectile Dysfunction
CountriesSingapore
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2010
First PostedDec 2010
Primary CompletionJan 2011
TodayJul 2026
First PostedDec 6, 2010
Enrollment StartDec 1, 2010
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 15.6 years ago
Interventions
Sildenafildrug
Orally Disintegrating Tablet, 50 mg, Single Dose
Sildenafildrug
Orally Disintegrating Tablet, 50 mg, Single Dose